ArticleResearch and reports in urology2026
Protective Effects of Cyclosporin H Against Sepsis-Induced Acute Kidney Injury via Modulation of Fpr1 Signaling and Inhibiting Pyroptosis.
Article in Research and reports in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to identify potential targets and mechanisms of sepsis-associated acute kidney injury (SA-AKI) using transcriptomic analysis. Methods: First, SA-AKI model was established by intraperitoneal LPS injection. Second, transcriptome sequencing was performed to analyze key targets and mechanisms in SA-AKI. Finally, we investigated the therapeutic effects of the Fpr1 inhibitor Cyclosporin H on the SA-AKI model. Results: H&E staining revealed intact renal structure in the control group, while the SA-AKI group showed structural damage, glomerular atrophy, and inflammatory cell infiltration. Serum levels of blood urea nitrogen and creatinine were significantly elevated in the SA-AKI group compared to controls (P<0.001). ELISA detection showed significantly higher TNF-α and IL-1β levels in both serum and kidney tissues of the SA-AKI group (P<0.001). Transcriptome analysis identified 209 differentially expressed genes between SA-AKI and control groups, with 194 upregulated and 15 downregulated genes. GO and KEGG analyses indicated that these genes primarily participated in leukocyte migration, phagocytosis, leukocyte chemotaxis, chemokine signaling pathways, and viral protein-cytokine interactions. qPCR confirmed significantly higher expression of Ubd, Fpr1, Fpr2, C3, B2m, and Itgam in the SA-AKI group (P<0.01). Following Cyclosporin H intervention, renal tissue damage was significantly ameliorated, with reduced renal function indicators and inflammatory markers. Additionally, TUNEL staining and transmission electron microscopy showed decreased TUNEL-positive cells, reduced mitochondrial damage, and fewer pyroptotic features after Cyclosporin H treatment. Western blot analysis demonstrated significantly decreased levels of ASC, Caspase-1, NLRP3, and IL-1β proteins after Cyclosporin H intervention (P<0.001). Conclusion: Fpr1 may serve as a key mediator in the SA-AKI. Cyclosporin H may improve sepsis-induced kidney injury and inflammation by inhibiting pyroptosis, providing a potential early therapeutic intervention.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.